Cancer Cell Int. 2021 Sep 16;21(1):493. doi: 10.1186/s12935-021-02071-y.
High expression of oncogene cadherin-6 correlates with tumor progression and a poor prognosis in gastric cancer.
Cancer cell international
Zongxian Zhao, Shuliang Li, Shilong Li, Jun Wang, Hai Lin, Weihua Fu
Affiliations
Affiliations
- Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin, China. [email protected].
- Department of Gastrointestinal Surgery, The Second People's Hospital of Liaocheng, Liaocheng, Shangdong, China. [email protected].
- Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin, China.
- Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin, China. [email protected].
PMID: 34530820
PMCID: PMC8447617 DOI: 10.1186/s12935-021-02071-y
Abstract
BACKGROUND: Gastric cancer (GC) is one of the most common and fatal cancers worldwide. Effective biomarkers to aid the early diagnosis of GC, as well as predict the course of disease, are urgently needed. Hence, we explored the role and function of cadherin-6 (CDH6) in the diagnosis and prognosis of gastric cancer.
METHODS: The expression levels of CDH6 in cancerous and normal gastric tissue were analyzed using multiple public databases. Gene set enrichment analysis (GSEA) was performed using The Cancer Genome Atlas (TCGA) dataset. The diagnostic efficiency of CDH6 expression in GC patients was determined through receiver operating characteristic (ROC) curve analysis. The associations between clinical variables and CDH6 expression were evaluated statistically, and the prognostic factors for overall survival were analyzed by univariate and multivariate Cox regression. 44 GC tissue samples, 20 donor-matched adjacent normal tissue samples, and associated detailed clinical information, were collected from the Tianjin Medical University General Hospital. CDH6 expression levels were determined for further validation.
RESULTS: CDH6 was upregulated in GC samples compared to normal gastric tissue. Furthermore, GSEA identified the tricarboxylic acid (TCA) cycle, extracellular matrix (ECM) receptor interaction, glyoxylate and dicarboxylate metabolism, oxidative phosphorylation, and the pentose phosphate pathway as differentially enriched in GC tissue samples. According to the area under the ROC curve (AUC) values (AUC = 0.829 in the TCGA and 0.966 in the GSE54129 dataset), CDH6 expression was associated with high diagnostic efficacy. Patients with high CDH6 levels in their GC tissues had a higher T number (according to the TNM classification) and a worse prognosis than those with low CDH6 expression. Univariate and multivariate Cox regression analysis showed that CDH6 was an independent risk factor for overall survival (univariate: HR = 1.305, P = 0.002, multivariate: HR = 1.481, P < 0.001).
CONCLUSION: CDH6 was upregulated in GC, and high CDH6 expression was indicative of a higher T number and a worse prognosis. Therefore, CDH6 represents a potentially independent molecular biomarker for the diagnostic and prognostic prediction of GC.
© 2021. The Author(s).
Keywords: Cadherin-6; Gastric cancer; Oncogene; Prognosis; Tumor progression
References
- Development. 1998 Mar;125(5):803-12 - PubMed
- Oncogenesis. 2017 Dec 22;6(12):402 - PubMed
- Am J Transl Res. 2020 Jun 15;12(6):3057-3067 - PubMed
- Cell Death Differ. 2011 Sep;18(9):1470-7 - PubMed
- Pathol Res Pract. 2019 May;215(5):1038-1048 - PubMed
- Int J Mol Sci. 2019 Jul 09;20(13): - PubMed
- World J Gastroenterol. 2018 Jul 14;24(26):2818-2832 - PubMed
- Tumour Biol. 2017 Jul;39(7):1010428317714626 - PubMed
- Breast Cancer Res. 2001;3(5):289-93 - PubMed
- Cells. 2019 Sep 20;8(10): - PubMed
- Eur J Cancer. 2011 Apr;47(6):934-45 - PubMed
- Mol Cell Neurosci. 2008 Sep;39(1):95-104 - PubMed
- Med Sci Monit. 2019 May 13;25:3537-3541 - PubMed
- Cancer Discov. 2017 Sep;7(9):1030-1045 - PubMed
- Cell Mol Life Sci. 2019 Apr;76(7):1299-1317 - PubMed
- Int J Mol Sci. 2020 Oct 15;21(20): - PubMed
- Cancer Manag Res. 2019 Dec 13;11:10477-10486 - PubMed
- PeerJ. 2018 Jul 2;6:e5180 - PubMed
- Front Pharmacol. 2018 Dec 05;9:1421 - PubMed
- FEBS Lett. 2012 Mar 23;586(6):924-33 - PubMed
- Epigenetics. 2016 Nov;11(11):780-790 - PubMed
- CA Cancer J Clin. 2021 May;71(3):209-249 - PubMed
- World J Surg Oncol. 2018 Jun 19;16(1):114 - PubMed
- J Mol Biol. 2000 Jun 9;299(3):551-72 - PubMed
- Lancet Oncol. 2008 Mar;9(3):279-87 - PubMed
- Oncotarget. 2016 Oct 25;7(43):69871-69882 - PubMed
- Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
- Oncol Lett. 2018 May;15(5):7415-7422 - PubMed
- Oncol Lett. 2018 Jun;15(6):9498-9506 - PubMed
- Nat Rev Genet. 2007 May;8(5):341-52 - PubMed
- JAMA Oncol. 2015 Apr;1(1):23-32 - PubMed
- Cancer Commun (Lond). 2019 Apr 29;39(1):22 - PubMed
- Trends Cell Biol. 2014 Sep;24(9):524-36 - PubMed
- Oncogene. 2017 Feb 2;36(5):667-677 - PubMed
- Bioessays. 1992 Nov;14(11):743-8 - PubMed
Publication Types